For more information or to apply for opportunities, please contact:
Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV and HIV infections, two global diseases with high levels of unmet need. Novira’s oral drugs target the capsid of the virus, and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company’s antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid inhibitors which feature a new mechanism of action.
Scott M. Rocklage, Ph.D.
Christian S. Schade
Chief Executive Officer
Osvaldo (Lalo) Flores, Ph.D.
Co-founder, President & Chief Scientific Officer
Anthony W. Ford-Hutchinson, Ph.D.
Independent Consultant to the Pharmaceutical Industry
Tim Shannon, M.D.
Venture Partner at Canaan Partners
Gianni Gromo, M.D., Ph.D.
Venture Partner at Versant Ventures